Novartis Lp(a) Drug: 2027 Wait for Heart Hope

Listen to this article · 10 min listen

Key Takeaways

  • Novartis’s key Phase 3 trial for their Lp(a)-targeting therapy, pelacarsen, has enrolled over 8,000 participants, indicating significant industry investment in this cardiovascular risk factor.
  • Despite promising Phase 2 data showing up to 80% reduction in Lp(a) levels, the primary outcome data for major adverse cardiovascular events (MACE) from the HORIZON study is not expected until late 2027, creating a prolonged wait for market entry.
  • The high prevalence of elevated Lp(a), affecting an estimated 20% of the global population, translates to hundreds of millions of individuals at increased risk for heart disease, underscoring the vast potential market for an effective therapeutic.
  • Current medical guidelines, such as those from the European Society of Cardiology, recommend Lp(a) testing for specific high-risk groups, but widespread routine screening remains contentious without an approved, specific treatment.
  • Drug development for Lp(a) is inherently complex due to its genetic determination and the need for long-term outcome studies, which often stretch over many years and require substantial capital investment.

An estimated 20% of the global population lives with elevated levels of lipoprotein(a), or Lp(a), a largely genetic and often overlooked risk factor for cardiovascular disease. This staggering figure represents hundreds of millions of individuals facing an increased, unaddressed threat to their heart health. The pharmaceutical industry, particularly players like Novartis and Ionis Pharmaceuticals, has poured significant resources into developing targeted therapies for Lp(a), yet the path to market approval is proving to be a formidable obstacle. Will these ambitious endeavors finally break through this long-standing drug development roadblock, or are we destined for more years of waiting?

The 8,000-Patient Enrollment Milestone: A Bet on a Billion-Dollar Market

Novartis, in collaboration with Ionis Pharmaceuticals, made a substantial commitment to Lp(a) reduction with their Phase 3 trial for pelacarsen (formerly TQJ230). The HORIZON study, a global cardiovascular outcomes trial, has successfully enrolled over 8,000 patients with established atherosclerotic cardiovascular disease (ASCVD) and elevated Lp(a). This is not a small undertaking. A trial of this magnitude requires immense logistical coordination and financial backing, signaling the companies’ strong belief in pelacarsen’s potential. According to a 2025 investor briefing from Novartis, the total direct cost for a Phase 3 cardiovascular outcomes trial of this scale can easily exceed $500 million, excluding the significant internal R&D expenditure that precedes it. This kind of investment is reserved for therapies targeting conditions with massive unmet needs and correspondingly large market opportunities, suggesting analysts predict a multi-billion dollar annual market if approved.

My interpretation of this data point is that the financial stakes are incredibly high, driving both urgency and caution. Novartis isn’t just testing a drug. They’re attempting to define a new therapeutic category in cardiovascular medicine. The sheer number of patients enrolled also reflects the difficulty in demonstrating a statistically significant reduction in major adverse cardiovascular events (MACE) in a population already on optimal standard-of-care therapies. Small effect sizes, while still clinically meaningful for a chronic condition, demand large cohorts to be proven. It’s a calculated risk, betting on a compound that showed impressive Lp(a) lowering in earlier phases to translate into hard clinical benefits.

The 80% Lp(a) Reduction in Phase 2: A Glimmer of Hope, Not a Guarantee

Earlier trials for pelacarsen, specifically the Phase 2 dose-finding study, generated considerable excitement within the cardiology community. That research demonstrated that pelacarsen could reduce Lp(a) levels by as much as 80% from baseline in patients with elevated Lp(a). For context, current lipid-lowering therapies like statins have minimal to no effect on Lp(a). This dramatic reduction is achieved through an antisense oligonucleotide (ASO) mechanism, which targets the messenger RNA responsible for producing apolipoprotein(a) in the liver, effectively shutting down the production of Lp(a) particles. This mechanism of action, first pioneered by Ionis Pharmaceuticals, is elegant in its specificity.

While an 80% reduction is undeniably impressive from a mechanistic standpoint, it’s important to remember that surrogate markers, no matter how compelling, do not always translate directly into improved clinical outcomes. We have seen this repeatedly in cardiovascular drug development. Powerful lipid-lowering agents have sometimes failed to reduce MACE, or have done so with unacceptable side effect profiles. The challenge for pelacarsen, and indeed for any Lp(a)-lowering drug, is to prove that this biochemical reduction leads to fewer heart attacks, strokes, and cardiovascular deaths. Without that, the drug remains a scientific curiosity rather than a medical breakthrough. The history of drug development is littered with compounds that looked fantastic on paper, or in Phase 2, but stumbled at the finish line.

The Late 2027 Outcome Data: A Marathon, Not a Sprint

Despite the advanced stage of the HORIZON trial, the primary outcome data for MACE is not expected until late 2027. This timeline is a stark reminder of the arduous nature of cardiovascular outcomes trials. These studies require patients to be followed for several years to accumulate a sufficient number of cardiovascular events to detect a statistically significant difference between the treatment and placebo groups. The average follow-up period for the HORIZON trial participants is projected to be around 4 to 5 years, commencing after their enrollment. Given that enrollment was completed in late 2023, the 2027 readout aligns with these long observational periods.

This extended timeline presents several challenges. For patients with high Lp(a), it means continued exposure to an elevated cardiovascular risk for years without a targeted therapy. For investors, it means tying up significant capital for an extended period, with no guarantee of a return. For the pharmaceutical companies, it means maintaining trial infrastructure, monitoring patients, and managing a massive dataset for half a decade. This waiting period also allows competitors to potentially catch up, though the lead established by Novartis and Ionis is substantial. The delay inherently increases the risk for all involved, but it is an unavoidable consequence of seeking definitive proof of benefit in a chronic disease setting. No one wants a drug approved on incomplete evidence, especially when dealing with such fundamental aspects of human health.

The 20% Global Prevalence: A Public Health Imperative

As mentioned, approximately 20% of the global population has elevated Lp(a) levels, defined typically as greater than 50 mg/dL or 125 nmol/L. This figure represents an enormous public health burden. Unlike traditional cholesterol markers, Lp(a) levels are largely genetically determined and do not respond significantly to lifestyle changes or existing lipid-lowering medications. This means that tens of millions of individuals are living with an unmodifiable, independent risk factor for cardiovascular disease, often without their knowledge.

The conventional wisdom among some clinicians has been that since there’s no specific treatment, there’s no point in routinely screening for Lp(a). I find this argument deeply problematic. While it’s true that the absence of a direct therapeutic option limits immediate intervention, knowing a patient’s Lp(a) status allows for a more complete risk assessment. It might prompt a more aggressive management of other modifiable risk factors like blood pressure, LDL cholesterol, and diabetes. It also helps patients with critical information about their own risk profile, potentially motivating stricter adherence to healthy lifestyle choices and existing therapies. The European Society of Cardiology (ESC) guidelines, for instance, recommend Lp(a) measurement at least once in a person’s lifetime to identify those with very high inherited Lp(a) concentrations, especially in individuals with premature ASCVD or a family history of premature ASCVD. This is a sensible approach, even without a specific drug.

The Conventional Wisdom on Lp(a) Screening: A Flawed Rationale

Many medical professionals still adhere to the belief that widespread Lp(a) screening is unnecessary because, until recently, there was no specific therapeutic intervention. Their argument centers on the idea that identifying a risk factor without an actionable treatment causes undue anxiety for patients and adds unnecessary costs to healthcare systems. This perspective, however, fundamentally misunderstands the role of risk assessment in preventive medicine.

I strongly disagree with this conventional wisdom. While it’s true that a specific drug for Lp(a) has been elusive, knowing a patient’s elevated Lp(a) level is immensely valuable. It reframes their overall cardiovascular risk. For example, a patient with borderline LDL cholesterol might be managed more aggressively with statins if they also have very high Lp(a). A patient with a strong family history of early heart disease, often attributed to “bad genes,” could have a clearer explanation for their risk, moving from vague genetic predisposition to a concrete, measurable factor. This knowledge allows for intensified management of all other modifiable risk factors. It can also inform decisions regarding aspirin therapy, blood pressure targets, and glucose control. The idea that information without a direct pharmaceutical solution is useless is a narrow view of clinical practice. Patients want to understand their health, and healthcare providers have a responsibility to provide as complete a picture as possible, even when all the puzzle pieces don’t yet have a perfect fit. The impending arrival of drugs like pelacarsen makes the argument for broader screening even stronger, as early identification will be key for future treatment eligibility.

The journey of Novartis and Ionis in tackling Lp(a) exemplifies the complexities of modern pharmaceuticals. Their substantial investment and the protracted timeline underscore the high stakes involved in bringing a novel therapy for heart health to market. While the wait for definitive outcomes data is long, the potential for a breakthrough in cardiovascular prevention remains a powerful motivator for continued research and development.

What is lipoprotein(a) or Lp(a)?

Lipoprotein(a), or Lp(a), is a type of low-density lipoprotein (LDL) particle that contains an additional protein called apolipoprotein(a). It is largely determined by genetics and high levels are an independent risk factor for atherosclerotic cardiovascular disease, including heart attacks and strokes.

Why is Lp(a) considered a “roadblock” in drug development?

Lp(a) has been a roadblock because, until recently, there were no specific drugs capable of significantly lowering its levels. Its genetic determination means lifestyle changes have minimal impact, making it a challenging target for pharmaceutical intervention, and outcomes trials require long follow-up periods.

What is pelacarsen and how does it work?

Pelacarsen is an investigational drug developed by Ionis Pharmaceuticals and licensed to Novartis. It is an antisense oligonucleotide (ASO) designed to reduce Lp(a) levels by targeting the messenger RNA (mRNA) in the liver that produces apolipoprotein(a), thereby inhibiting the synthesis of Lp(a) particles.

When is the HORIZON study expected to release its primary outcome data?

The primary outcome data for major adverse cardiovascular events (MACE) from the HORIZON study, which is evaluating pelacarsen, is anticipated to be released in late 2027. This timeline reflects the long follow-up period required for cardiovascular outcomes trials.

Should I get my Lp(a) levels tested?

Medical guidelines, such as those from the European Society of Cardiology, recommend Lp(a) measurement at least once in a person’s lifetime, especially for individuals with a family history of premature cardiovascular disease or those who have already experienced an atherosclerotic cardiovascular event. Discussing this with your doctor is the best course of action.

Editorial Team

The Editorial Team at News Snook is a group of writers and editors who cover the stories shaping their industry. They research each story and publish under a shared desk byline — experts in their fields, working as one team.